BETABiohacksAI is a research tool for informational purposes only. All outputs are computational hypothesis candidates — not confirmed mechanisms, not medical advice, and not a substitute for professional medical judgment. Independent experimental validation is always required.
BiohacksAI is an evolving scientific literature platform. New compounds and evidence are indexed continuously.
B
○

Cabergoline

An ergoline derivative and dopamine D2-agonist that inhibits PROLACTIN secretion. It is used in the management of HYPERPROLACTINEMIA, and to suppress lactation following childbirth for medical reasons. Cabergoline is also used in the management of PARKINSON DISEASE.

299+ PubMed studies analyzed · 35 RCTs · Evidence Score: 55

Research Domains

Cabergoline has been studied across 19 research domains including 🌤️ Mood & Depression, 🧠 Focus & Attention, 🔬 Oncology, 🧬 Hormones, 🧠 Neuroprotection. The primary research focus is 🌤️ Mood & Depression with 56% of studies addressing this area.

Similar Compounds by Shared Targets

The following compounds share molecular targets with Cabergoline, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.

paliperidone
15 shared targets
risperidone
19 shared targets
Dihydroergocornine
12 shared targets
brexpiprazole
18 shared targets
nantenine
15 shared targets
silodosin
13 shared targets
penfluridol
14 shared targets
olanzapine
16 shared targets
Lysergic
20 shared targets
ritanserin
16 shared targets
Loading evidence profile...

This evidence profile for Cabergoline is generated deterministically from 299 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.

Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.